<DOC>
	<DOCNO>NCT00205751</DOCNO>
	<brief_summary>This international multi-center prospective , double randomize , open , controlled phase III study phase II entrance phase compare therapeutic efficacy thalidomide plus dexamethasone conventional melphalan plus prednisone newly diagnose myeloma patient .</brief_summary>
	<brief_title>Thalidomide/Dexamethasone vs MP Induction Therapy Thalidomide/Intron A v Intron A Maintenance Therapy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients Multiple Myeloma IgG , IgA , IgD , IgE , IgM lambda kappa light chain , low secretory nonsecretory disease WHO performance status 0,1,2 , 3 No prior treatment multiple myeloma Clear requirement treatment ( usually Durie/Salmon stage II III ) Anticipated life expectancy least 3 month Adequate organ function Minimum recovery period 2 week follow major surgical procedure entry study Women , sterilize via hysterectomy bilateral tubal ligation least one year postmenopausal Age least 19 year , upper age limit patient must inform must sign informed consent Extramedullary plasmocytoma solitary plasmocytoma without evidence dissemination disease Benign monoclonal gammopathy Multiple myeloma IgM without osteolytic bone lesion Smouldering myeloma More 3 irradiation field Irreversible performance status WHO4 Prior treatment myeloma follow : chemotherapeutic immunomodulatory agent , corticosteroid , antiangiogenic agent investigational drug Women childbearing potential Preexisting peripheral polyneuropathy Congestive heart failure NYHA III , IV Acute infection require systemic antibiotic study entry resolve Any uncontrolled underlying medical condition ( eg diabetes , glaucoma ) Second primary malignancy ( exception cervical carcinoma situ nonmyeloma skin malignancy ) unless patient diseasefree least three year</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>first line treatment</keyword>
	<keyword>thalidomide</keyword>
	<keyword>melphalan</keyword>
</DOC>